PF-08634404 / 3SBio, Pfizer - LARVOL DELTA

A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC). (ASCO 2026) - P2 | "Pts received SSGJ-707 5 mg/kg or 10 mg/kg Q3W + chemo (carboplatin AUC 5 + paclitaxel 175 mg/m2) Q3W for 6 cycles, followed by SSGJ-707 maintenance tx until loss of clinical benefit or intolerable toxicity for up to 2 years. SSGJ-707 + chemo demonstrated promising efficacy with a manageable safety profile in pts with tx-naive advanced/recurrent EC, supporting further investigation of SSGJ-707 in these pts. aOne additional pt in the 10 mg/kg group confirmed in Dec."

Bispecific • Clinical • IO biomarker • Metastases • P2 data • Cardiovascular • Endocrine Disorders • Endometrial Cancer • Oncology • Renal Disease • Solid Tumor • Thrombosis

Updated results from a phase 2 trial of SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). (ASCO 2026) - P2, P3 | "With longer follow-up, SSGJ-707 monotherapy continues to show promising efficacy with a manageable safety profile in pts with treatment-naive advanced NSCLC across histology and PD-L1 expression subgroups. These results supported initiation of the phase 3 study (Symbiotic-Lung-01) of SSGJ-707 with platinum-based chemotherapy in 1L squamous (SQ) and nonsquamous (NSQ) NSCLC irrespective of TPS (NCT07222566)."

Bispecific • Clinical • IO biomarker • Metastases • Monotherapy • P2 data • Cardiovascular • Hypertension • Infectious Disease • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Symbiotic-GU-08: Phase 1b/2 study of PF-08634404, a PD-1/VEGF bispecific antibody, with or without other anticancer agents in patients (pts) with locally advanced or metastatic renal cell carcinoma (la/mRCC) (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-1

Symbiotic-Lung-10: A Phase 2 Trial of PD-1/VEGF Bispecific Antibody, PF-08634404, as Monotherapy or in Combination in NSCLC (IASLC-WCLC 2026) - P2 | "Patients will receive neoadjuvant PF-08634404 plus platinum-doublet chemotherapy (carboplatin + paclitaxel for squamous or carboplatin + pemetrexed for non-squamous) for 3 cycles, with an optional fourth cycle for patients deriving clinical benefit. The primary endpoint is safety. Secondary endpoints include objective response rate and progression-free survival and overall survival."

Bispecific • IO biomarker • Monotherapy • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • PD-1 • PD-L1

Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: updated results (ESMO 2026) - No abstract available

Bispecific • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1

Symbiotic-Lung-14: A Phase 2 Trial of PD-1/VEGF Bispecific Antibody, PF-08634404, Plus Chemotherapy in 1L Transformed SCLC (IASLC-WCLC 2026) - P2 | "PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets programmed death 1 (PD-1) and vascular endothelial growth factor (VEGF)...Approximately 40 patients will be enrolled to receive PF-08634404 in combination with etoposide and carboplatin, followed by maintenance therapy with PF-08634404...Exploratory endpoints include quality of life and biomarkers. Enrollment has begun."

Bispecific • IO biomarker • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • EGFR • PD-1

Symbiotic-GYN-18 (GOG-3145/ENGOT-EN37/APGOT-EN6/LACOG 0426-EVA): Phase 3 study of PF-08634404, a PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients (pts) with advanced or recurrent mismatch repair proficient (pMMR) endometrial cancer (EC) (ESMO 2026) - No abstract available

Bispecific • Clinical • Combination therapy • Metastases • Mismatch repair • P3 data • pMMR • Endometrial Cancer • Oncology • Solid Tumor

Symbiotic-GI-16: A phase II/III study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with chemotherapy (chemo) in patients (pts) with locally advanced (la) or metastatic (m) gastroesophageal adenocarcinoma (GEA) (ESMO-GI 2026) - P2/3 | "In the phase 3 portion, ≈800 pts will be randomized 1:1 (stratified by region [North America, Asia, or rest of world], ECOG PS [0 or 1], and chemo [mFOLFOX6 or CAPOX]) to receive inv choice of chemo (mFOLFOX6 or CAPOX) + either PF-08634404 or nivolumab...Table: 615TiP BICR, blinded independent central review; PFS2, PFS after next-line therapy. a Per RECIST 1.1"

Bispecific • Clinical • Combination therapy • IO biomarker • Metastases • P2/3 data • Colorectal Cancer • Esophageal Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC). (ASCO 2026) - P3 | "The addition of biological therapies (eg, bevacizumab [bev], an anti-VEGF monoclonal antibody) to immune checkpoint inhibitors (ICIs) has demonstrated a synergistic antitumor effect in solid tumors...A phase 2 study of PF-08634404 with XELOX or mFOLFOX6 demonstrated promising antitumor activity with a manageable safety profile in first-line (1L) mCRC (Xu X, ESMO 2025; Abstract 796P)...Secondary endpoints include PFS by investigator, objective response rate, duration of response, PFS after next-line therapy, safety/tolerability, pharmacokinetics, immunogenicity, and patient-reported outcomes. Enrollment began in December 2025."

Bispecific • Clinical • Combination therapy • IO biomarker • Metastases • P3 data • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • BRAF • MSI • PD-1

PF-08634404: “Ph 2 Data: Robust Activity with PF’4404 Monotherapy at Selected Pivotal Dose in 1L PD-L1+ NSCLC”; Non-small cell lung cancer (Pfizer) - Q2 2026 Results

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology

PF-08634404: Initiation of P3 trial (NCT07578649) for 1L advanced or recurrent mismatch repair proficient endometrial cancer in H2 2026 (Pfizer) - Q2 2026 Results: Initiation of P1b/2 trial (NCT07421700) in combination with Padcev for 1L metastatic urothelial cancer in H2 2026

New P1/2 trial • New P3 trial • pMMR • Bladder Cancer • Endometrial Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Urothelial Cancer

PF-08634404: Initiation of trial for early-stage NSCLC in H2 2026/ H1 2027 (Pfizer) - Q2 2026 Results

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology

PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415) (KCRS 2026) - P1/2 | "Its affinity for soluble VEGF-A is approximately 30-fold and 60-fold higher than that of ivonescimab and bevacizumab, respectively, resulting in deeper and more potent VEGF inhibition in vitro...A phase 1b/2 study (Symbiotic-GU-08) in patients with newly diagnosed advanced or metastatic RCC is being conducted to evaluate the efficacy and safety of PF-08634404, either as monotherapy or in combination with ipilimumab (anti–CTLA-4) or axitinib (VEGF tyrosine kinase inhibitor) (NCT07227415)...Previously presented in part at the 2026 AACR Annual Meeting. Keywords Renal Cell Carcinoma, VEGF, PD-1, immunotherapy"

Bispecific • Colorectal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • FLT1 • PD-1

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: Pfizer | N=220 ➔ 800

Enrollment change • Trial initiation date • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=182 | Recruiting | Sponsor: Pfizer | N=47 ➔ 182

Enrollment change • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: Pfizer

New P3 trial • Colorectal Cancer • Oncology • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=550 | Not yet recruiting | Sponsor: Pfizer

New P2/3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=550 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=550 | Recruiting | Sponsor: Pfizer | N=182 ➔ 550

Enrollment change • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - P3 | N=800 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov) - P1/2 | N=162 | Recruiting | Sponsor: Pfizer

Trial initiation date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer (clinicaltrials.gov) - P1/2 | N=132 | Not yet recruiting | Sponsor: Pfizer

Monotherapy • New P1/2 trial • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=345 | Recruiting | Sponsor: Pfizer

New P3 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=1500 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor